Harnessing the power of yeast to unravel the molecular basis of neurodegeneration

Journal of Neurochemistry

Volumn 127, Issue 4, 2013, Pages 438-452

  Tenreiro, Sandra ^a   Munder, Matthias C ^c   Alberti, Simon ^c   Outeiro, Tiago F ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

amyloid; neurodegeneration; prion; protein aggregation; protein misfolding; S. cerevisiae

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; COPPER ZINC SUPEROXIDE DISMUTASE; FUSED IN SARCOMA PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; LEUCINE RICH REPEAT KINASE 2; OPTINEURIN; PROTEIN ATP13A2; RNA; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATP13A2 GENE; DISEASE MODEL; FUS GENE; GENE; GENETIC ASSOCIATION; HNRNPA1 GENE; HNRNPA2B1 GENE; HUMAN; HUNTINGTON CHOREA; LRRK2 GENE; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OPTN GENE; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SACCHAROMYCES CEREVISIAE; SNCA GENE; SOD1 GENE; TDP43 GENE;

AMYLOID; NEURODEGENERATION; PRION; PROTEIN AGGREGATION; PROTEIN MISFOLDING; S. CEREVISIAE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PRIONS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; SACCHAROMYCES CEREVISIAE;

ANIMALIA; EUKARYOTA; SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

EID: 84887107990     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12271     Document Type: Review

References (161)

1. Akerfelt M., Morimoto R. I., and, Sistonen L., (2010) Heat shock factors: integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 11, 545-555.
2. Alberti S., Gitler A. D., and, Lindquist S., (2007) A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast 24, 913-919.
3. Alberti S., Halfmann R., King O., Kapila A., and, Lindquist S., (2009) A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137, 146-158.
4. Alberti S., Halfmann R., and, Lindquist S., (2010) Biochemical, cell biological, and genetic assays to analyze amyloid and prion aggregation in yeast. Methods Enzymol. 470, 709-734.
5. Apostol B. L., Kazantsev A., Raffioni S., et al,. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci. USA 100, 5950-5955.
6. Apostol B. L., Illes K., Pallos J., et al,. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 15, 273-285.
7. Arighi C. N., Hartnell L. M., Aguilar R. C., Haft C. R., and, Bonifacino J. S., (2004) Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J. Cell Biol. 165, 123-133.
8. Armakola M., Hart M. P., and, Gitler A. D., (2011) TDP-43 toxicity in yeast. Methods 53, 238-245.
9. Armakola M., Higgins M. J., Figley M. D., et al,. (2012) Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet. 44, 1302-1309.
10. Bach S., Talarek N., Andrieu T., et al,. (2003) Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat. Biotechnol. 21, 1075-1081.
11. Bach S., Tribouillard D., Talarek N., Desban N., Gug F., Galons H., and, Blondel M., (2006) A yeast-based assay to isolate drugs active against mammalian prions. Methods 39, 72-77.
12. Bagriantsev S., and, Liebman S., (2006) Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol. 4, 32.
13. Bagriantsev S. N., Kushnirov V. V., and, Liebman S. W., (2006) Analysis of amyloid aggregates using agarose gel electrophoresis. Methods Enzymol. 412, 33-48.
14. Barros M. H., da Cunha F. M., Oliveira G. A., Tahara E. B., and, Kowaltowski A. J., (2010) Yeast as a model to study mitochondrial mechanisms in ageing. Mech. Ageing Dev. 131, 494-502.
15. Bharadwaj P., Martins R., and, Macreadie I., (2010) Yeast as a model for studying Alzheimer's disease. FEMS Yeast Res. 10, 961-969.
16. Bocharova N. A., Sokolov S. S., Knorre D. A., Skulachev V. P., and, Severin F. F., (2008) Unexpected link between anaphase promoting complex and the toxicity of expanded polyglutamines expressed in yeast. Cell Cycle 7, 3943-3946.
17. Bodner R. A., Outeiro T. F., Altmann S., et al,. (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl Acad. Sci. USA 103, 4246-4251.
18. Bonifacino J. S., and, Glick B. S., (2004) The mechanisms of vesicle budding and fusion. Cell 116, 153-166.
19. Bonifacino J. S., and, Hurley J. H., (2008) Retromer. Curr. Opin. Cell Biol. 20, 427-436.
20. Bonifacino J. S., and, Rojas R., (2006) Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7, 568-579.
21. Bosco D. A., Lemay N., Ko H. K., et al,. (2010) Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 19, 4160-4175.
22. Botstein D., and, Fink G. R., (2011) Yeast: an experimental organism for 21st Century biology. Genetics 189, 695-704.
23. Braun R. J., (2012) Mitochondrion-mediated cell death: dissecting yeast apoptosis for a better understanding of neurodegeneration. Front. Oncol. 2, 182.
24. Braun R. J., Buttner S., Ring J., Kroemer G., and, Madeo F., (2010) Nervous yeast: modeling neurotoxic cell death. Trends Biochem. Sci. 35, 135-144.
25. Brodsky J. L., and, Skach W. R., (2011) Protein folding and quality control in the endoplasmic reticulum: recent lessons from yeast and mammalian cell systems. Curr. Opin. Cell Biol. 23, 464-475.
26. Buttner S., Bitto A., Ring J., et al,. (2008) Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. J. Biol. Chem. 283, 7554-7560.
27. Campesan S., Green E. W., Breda C., Sathyasaikumar K. V., Muchowski P. J., Schwarcz R., Kyriacou C. P., and, Giorgini F., (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 21, 961-966.
28. Chan E. T., and, Cherry J. M., (2012) Considerations for creating and annotating the budding yeast Genome Map at SGD: a progress report. Database (Oxford) 2012, bar057.
29. Chartier-Harlin M. C., Kachergus J., Roumier C., et al,. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
30. Chen Q., Thorpe J., and, Keller J. N., (2005) Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem. 280, 30009-30017.
31. Chen B., Retzlaff M., Roos T., and, Frydman J., (2011) Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 3, a004374.
32. Cherry J. M., Hong E. L., Amundsen C., et al,. (2012) Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic Acids Res. 40, D700-D705.
33. Chesi A., Kilaru A., Fang X., Cooper A. A., and, Gitler A. D., (2012) The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast. PLoS ONE 7, e34178.
34. Cohen A., Ross L., Nachman I., and, Bar-Nun S., (2012) Aggregation of polyQ proteins is increased upon yeast aging and affected by Sir2 and Hsf1: novel quantitative biochemical and microscopic assays. PLoS ONE 7, e44785.
35. Colombrita C., Zennaro E., Fallini C., Weber M., Sommacal A., Buratti E., Silani V., and, Ratti A., (2009) TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 111, 1051-1061.
36. Cooper A. A., Gitler A. D., Cashikar A., et al,. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328.
37. Corson L. B., Strain J. J., Culotta V. C., and, Cleveland D. W., (1998) Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc. Natl Acad. Sci. USA 95, 6361-6366.
38. Coustou V., Deleu C., Saupe S., and, Begueret J., (1997) The protein product of the het-s heterokaryon incompatibility gene of the fungus Podospora anserina behaves as a prion analog. Proc. Natl Acad. Sci. USA 94, 9773-9778.
39. Couthouis J., Hart M. P., Shorter J., et al,. (2011) A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl Acad. Sci. USA 108, 20881-20890.
40. Daigle J. G., Lanson N. A., Smith R. B., et al,. (2012) RNA binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum. Mol. Genet. 22, 1193-1205.
41. Dobson C. M., (2003) Protein folding and misfolding. Nature 426, 884-890.
42. Dong J., Bloom J. D., Goncharov V., Chattopadhyay M., Millhauser G. L., Lynn D. G., Scheibel T., and, Lindquist S., (2007) Probing the role of PrP repeats in conformational conversion and amyloid assembly of chimeric yeast prions. J. Biol. Chem. 282, 34204-34212.
43. Drummond D. A., and, Wilke C. O., (2008) Mistranslation-induced protein misfolding as a dominant constraint on coding-sequence evolution. Cell 134, 341-352.
44. Duennwald M. L., and, Lindquist S., (2008) Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev. 22, 3308-3319.
45. Duennwald M. L., and, Shorter J., (2010) Countering amyloid polymorphism and drug resistance with minimal drug cocktails. Prion 4, 244-251.
46. Duennwald M. L., Jagadish S., Giorgini F., Muchowski P. J., and, Lindquist S., (2006a) A network of protein interactions determines polyglutamine toxicity. Proc. Natl Acad. Sci. USA 103, 11051-11056.
47. Duennwald M. L., Jagadish S., Muchowski P. J., and, Lindquist S., (2006b) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc. Natl Acad. Sci. USA 103, 11045-11050.
48. Duennwald M. L., Echeverria A., and, Shorter J., (2012) Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol. 10, e1001346.
49. Ehrnhoefer D. E., Duennwald M., Markovic P., et al,. (2006) Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 15, 2743-2751.
50. Elden A. C., Kim H. J., Hart M. P., et al,. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075.
51. Fields S., and, Johnston M., (2005) Cell biology. Whither model organism research? Science 307, 1885-1886.
52. Flower T. R., Clark-Dixon C., Metoyer C., Yang H., Shi R., Zhang Z., and, Witt S. N., (2007) YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. J. Cell Biol. 177, 1091-1104.
53. Gelperin D. M., White M. A., Wilkinson M. L., et al,. (2005) Biochemical and genetic analysis of the yeast proteome with a movable ORF collection. Genes Dev. 19, 2816-2826.
54. Giorgini F., Guidetti P., Nguyen Q., Bennett S. C., and, Muchowski P. J., (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 37, 526-531.
55. Gitler A. D., Chesi A., Geddie M. L., et al,. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308-315.
56. Goeckeler J. L., and, Brodsky J. L., (2010) Molecular chaperones and substrate ubiquitination control the efficiency of endoplasmic reticulum-associated degradation. Diabetes Obes. Metab. 12 (Suppl 2), 32-38.
57. Goffeau A., Barrell B. G., Bussey H., et al,. (1996) Life with 6000 genes. Science 274, 563-567.
58. Gong H., Romanova N. V., Allen K. D., Chandramowlishwaran P., Gokhale K., Newnam G. P., Mieczkowski P., Sherman M. Y., and, Chernoff Y. O., (2012) Polyglutamine toxicity is controlled by prion composition and gene dosage in yeast. PLoS Genet. 8, e1002634.
59. Gorman A. M., (2008) Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J. Cell Mol. Med. 12, 2263-2280.
60. Goyer C., Altmann M., Lee H. S., Blanc A., Deshmukh M., Woolford J. L. Jr, Trachsel H., and, Sonenberg N., (1993) TIF4631 and TIF4632: two yeast genes encoding the high-molecular-weight subunits of the cap-binding protein complex (eukaryotic initiation factor 4F) contain an RNA recognition motif-like sequence and carry out an essential function. Mol. Cell. Biol. 13, 4860-4874.
61. Griffioen G., Duhamel H., Van Damme N., Pellens K., Zabrocki P., Pannecouque C., van Leuven F., Winderickx J., and, Wera S., (2006) A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim. Biophys. Acta 1762, 312-318.
62. Grimminger-Marquardt V., and, Lashuel H. A., (2010) Structure and function of the molecular chaperone Hsp104 from yeast. Biopolymers 93, 252-276.
63. von der Haar T., Josse L., Wright P., Zenthon J., and, Tuite M. F., (2007) Development of a novel yeast cell-based system for studying the aggregation of Alzheimer's disease-associated Abeta peptides in vivo. Neurodegener. Dis. 4, 136-147.
64. Halfmann R., Jarosz D. F., Jones S. K., Chang A., Lancaster A. K., and, Lindquist S., (2012) Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature 482, 363-368.
65. Heinicke S., Livstone M. S., Lu C., Oughtred R., Kang F., Angiuoli S. V., White O., Botstein D., and, Dolinski K., (2007) The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists. PLoS ONE 2, e766.
66. Hughes R. E., Lo R. S., Davis C., Strand A. D., Neal C. L., Olson J. M., and, Fields S., (2001) Altered transcription in yeast expressing expanded polyglutamine. Proc. Natl Acad. Sci. USA 98, 13201-13206.
67. Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-983.
68. Johnson B. S., McCaffery J. M., Lindquist S., and, Gitler A. D., (2008) A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 105, 6439-6444.
69. Johnson B. S., Snead D., Lee J. J., McCaffery J. M., Shorter J., and, Gitler A. D., (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284, 20329-20339.
70. Jossé L., Marchante R., Zenthon J., von der Haar T., and, Tuite M. F., (2012) Probing the role of structural features of mouse PrP in yeast by expression as Sup35-PrP fusions. Prion 6, 201-210.
71. Joyner P. M., Matheke R. M., Smith L. M., and, Cichewicz R. H., (2010) Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice. J. Proteome Res. 9, 404-412.
72. Ju S., Tardiff D. F., Han H., et al,. (2011) A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol. 9, e1001052.
73. Karathia H., Vilaprinyo E., Sorribas A., and, Alves R., (2011) Saccharomyces cerevisiae as a model organism: a comparative study. PLoS ONE 6, e16015.
74. Kim H. J., Kim N. C., Wang Y. D., et al,. (2013) Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467-473.
75. King O. D., Gitler A. D., and, Shorter J., (2012) The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462, 61-80.
76. Klein C., and, Westenberger A., (2012) Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2, a008888.
77. Klionsky D. J., Cuervo A. M., and, Seglen P. O., (2007) Methods for monitoring autophagy from yeast to human. Autophagy 3, 181-206.
78. Kritzer J. A., Hamamichi S., McCaffery J. M., Santagata S., Naumann T. A., Caldwell K. A., Caldwell G. A., and, Lindquist S., (2009) Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat. Chem. Biol. 5, 655-663.
79. Krobitsch S., and, Lindquist S., (2000) Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl Acad. Sci. USA 97, 1589-1594.
80. Kruger R., Kuhn W., Muller T., et al,. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
81. Kryndushkin D., and, Shewmaker F., (2011) Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity. Prion 5, 250-257.
82. Kryndushkin D., Wickner R. B., and, Shewmaker F., (2011) FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell 2, 223-236.
83. Kryndushkin D., Ihrke G., Piermartiri T. C., and, Shewmaker F., (2012) A yeast model of optineurin proteinopathy reveals a unique aggregation pattern associated with cellular toxicity. Mol. Microbiol. 86, 1531-1547.
84. Lagier-Tourenne C., and, Cleveland D. W., (2009) Rethinking ALS: the FUS about TDP-43. Cell 136, 1001-1004.
85. Lamesch P., Li N., Milstein S., et al,. (2007) hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics 89, 307-315.
86. Lashuel H. A., and, Pappu R. V., (2009) Amyloids go genomic: insights regarding the sequence determinants of prion formation from genome-wide studies. ChemBioChem 10, 1951-1954.
87. Lashuel H. A., Overk C. R., Oueslati A., and, Masliah E., (2012) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48.
88. Lee Y., Dawson V. L., and, Dawson T. M., (2012) Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb. Perspect. Med. 2, a009324. doi: 10.1101/cshperspect.a009324.
89. Lill C. M., Roehr J. T., McQueen M. B., et al,. (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 8, e1002548.
90. Liu T. T., Gomez T. S., Sackey B. K., Billadeau D. D., and, Burd C. G., (2012) Rab GTPase regulation of retromer-mediated cargo export during endosome maturation. Mol. Biol. Cell 23, 2505-2515.
91. Malinovska L., Kroschwald S., and, Alberti S., (2013) Protein disorder, prion propensities, and self-organizing macromolecular collectives. Biochim. Biophys. Acta 1834, 918-931. doi: 10.1016/j.bbapap.2013.01.003.
92. Marques O., and, Outeiro T. F., (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 3, e350.
93. Mason R. P., and, Giorgini F., (2011) Modeling Huntington disease in yeast: perspectives and future directions. Prion 5, 269-276.
94. Meriin A. B., Zhang X., He X., Newnam G. P., Chernoff Y. O., and, Sherman M. Y., (2002) Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J. Cell Biol. 157, 997-1004.
95. Meriin A. B., Zhang X., Miliaras N. B., Kazantsev A., Chernoff Y. O., McCaffery J. M., Wendland B., and, Sherman M. Y., (2003) Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol. Cell. Biol. 23, 7554-7565.
96. Meriin A. B., Zhang X., Alexandrov I. M., Salnikova A. B., Ter-Avanesian M. D., Chernoff Y. O., and, Sherman M. Y., (2007) Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J. 21, 1915-1925.
97. Miller-Fleming L., Giorgini F., and, Outeiro T. F., (2008) Yeast as a model for studying human neurodegenerative disorders. Biotechnol. J. 3, 325-338.
98. Muchowski P. J., Schaffar G., Sittler A., Wanker E. E., Hayer-Hartl M. K., and, Hartl F. U., (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl Acad. Sci. USA 97, 7841-7846.
99. Munch C., and, Bertolotti A., (2012) Propagation of the prion phenomenon: beyond the seeding principle. J. Mol. Biol. 421, 491-498.
100. Neumann M., (2009) Molecular neuropathology of TDP-43 proteinopathies. Int. J. Mol. Sci. 10, 232-246.
101. Neumann M., Sampathu D. M., Kwong L. K., et al,. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
102. Nielsen M. S., Gustafsen C., Madsen P., et al,. (2007) Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol. Cell. Biol. 27, 6842-6851.
103. O'Brien R. J., and, Wong P. C., (2011) Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34, 185-204.
104. Orr H. T., and, Zoghbi H. Y., (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621.
105. Osherovich L. Z., Cox B. S., Tuite M. F., and, Weissman J. S., (2004) Dissection and design of yeast prions. PLoS Biol. 2, E86.
106. Outeiro T. F., and, Giorgini F., (2006) Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnol. J. 1, 258-269.
107. Outeiro T. F., and, Lindquist S., (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772-1775.
108. Park S. K., Pegan S. D., Mesecar A. D., Jungbauer L. M., LaDu M. J., and, Liebman S. W., (2011) Development and validation of a yeast high-throughput screen for inhibitors of Abeta(4)(2) oligomerization. Dis. Model Mech. 4, 822-831.
109. Petranovic D., Tyo K., Vemuri G. N., and, Nielsen J., (2010) Prospects of yeast systems biology for human health: integrating lipid, protein and energy metabolism. FEMS Yeast Res. 10, 1046-1059.
110. Petroi D., Popova B., Taheri-Talesh N., Irniger S., Shahpasandzadeh H., Zweckstetter M., Outeiro T. F., and, Braus G. H., (2012) Aggregate clearance of alpha-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J. Biol. Chem. 287, 27567-27579.
111. Polymeropoulos M. H., Lavedan C., Leroy E., et al,. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
112. Rabizadeh S., Gralla E. B., Borchelt D. R., et al,. (1995) Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc. Natl Acad. Sci. USA 92, 3024-3028.
113. Rinaldi T., Dallabona C., Ferrero I., Frontali L., and, Bolotin-Fukuhara M., (2010) Mitochondrial diseases and the role of the yeast models. FEMS Yeast Res. 10, 1006-1022.
114. Roberts B. E., Duennwald M. L., Wang H., Chung C., Lopreiato N. P., Sweeny E. A., Knight M. N., and, Shorter J., (2009) A synergistic small-molecule combination directly eradicates diverse prion strain structures. Nat. Chem. Biol. 5, 936-946.
115. Rual J. F., Hirozane-Kishikawa T., Hao T., et al,. (2004) Human ORFeome version 1.1: a platform for reverse proteomics. Genome Res. 14, 2128-2135.
116. Rual J. F., Venkatesan K., Hao T., et al,. (2005) Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1178.
117. Sampaio-Marques B., Felgueiras C., Silva A., et al,. (2012) SNCA (alpha-synuclein)-induced toxicity in yeast cells is dependent on sirtuin 2 (Sir2)-mediated mitophagy. Autophagy 8, 1494-1509.
118. Sarkar S., Perlstein E. O., Imarisio S., et al,. (2007) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3, 331-338.
119. Saupe S. J., (2003) New anti-prion drugs make yeast blush. Trends Biotechnol. 21, 516-519.
120. Schmidt K., Wolfe D. M., Stiller B., and, Pearce D. A., (2009) Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem. Biophys. Res. Commun. 383, 198-202.
121. Schwer B., and, Verdin E., (2008) Conserved metabolic regulatory functions of sirtuins. Cell Metab. 7, 104-112.
122. Shao J., and, Diamond M. I., (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 Spec No. 2, R115-R123.
123. Sharma N., Brandis K. A., Herrera S. K., Johnson B. E., Vaidya T., Shrestha R., and, Debburman S. K., (2006) alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J. Mol. Neurosci. 28, 161-178.
124. Sheerin U. M., Charlesworth G., Bras J., et al,. (2012) Screening for VPS35 mutations in Parkinson's disease. Neurobiol. Aging 33 (838), e831-e835.
125. Shin N., Jeong H., Kwon J., et al,. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314, 2055-2065.
126. Shorter J., (2010) Emergence and natural selection of drug-resistant prions. Mol. BioSyst. 6, 1115-1130.
127. Si K., Lindquist S., and, Kandel E. R., (2003) A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 115, 879-891.
128. Singleton A. B., Farrer M., Johnson J., et al,. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
129. Sokolov S., Pozniakovsky A., Bocharova N., Knorre D., and, Severin F., (2006) Expression of an expanded polyglutamine domain in yeast causes death with apoptotic markers. Biochim. Biophys. Acta 1757, 660-666.
130. Solans A., Zambrano A., Rodriguez M., and, Barrientos A., (2006) Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum. Mol. Genet. 15, 3063-3081.
131. Soper J. H., Roy S., Stieber A., Lee E., Wilson R. B., Trojanowski J. Q., Burd C. G., and, Lee V. M., (2008) Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell 19, 1093-1103.
132. Sorolla M. A., Nierga C., Rodriguez-Colman M. J., Reverter-Branchat G., Arenas A., Tamarit J., Ros J., and, Cabiscol E., (2011) Sir2 is induced by oxidative stress in a yeast model of Huntington disease and its activation reduces protein aggregation. Arch. Biochem. Biophys. 510, 27-34.
133. Soto C., (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49-60.
134. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., and, Goedert M., (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
135. Spires-Jones T. L., Stoothoff W. H., de Calignon A., Jones P. B., and, Hyman B. T., (2009) Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 32, 150-159.
136. Su L. J., Auluck P. K., Outeiro T. F., et al,. (2010) Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis. Model Mech. 3, 194-208.
137. Sun Z., Diaz Z., Fang X., Hart M. P., Chesi A., Shorter J., and, Gitler A. D., (2011) Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 9, e1000614.
138. Suzuki G., Shimazu N., and, Tanaka M., (2012) A yeast prion, Mod5, promotes acquired drug resistance and cell survival under environmental stress. Science 336, 355-359.
139. Tenreiro S., and, Outeiro T. F., (2010) Simple is good: yeast models of neurodegeneration. FEMS Yeast Res. 10, 970-979.
140. Thevandavakkam M. A., Schwarcz R., Muchowski P. J., and, Giorgini F., (2010) Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol. Disord. Drug Targets 9, 791-800.
141. Treusch S., Hamamichi S., Goodman J. L., et al,. (2011) Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334, 1241-1245.
142. Tribouillard D., Bach S., Gug F., et al,. (2006) Using budding yeast to screen for anti-prion drugs. Biotechnol. J. 1, 58-67.
143. Tribouillard D., Gug F., Galons H., Bach S., Saupe S. J., and, Blondel M., (2007) Antiprion drugs as chemical tools to uncover mechanisms of prion propagation. Prion 1, 48-52.
144. Usenovic M., Knight A. L., Ray A., Wong V., Brown K. R., Caldwell G. A., Caldwell K. A., Stagljar I., and, Krainc D., (2012) Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Hum. Mol. Genet. 21, 3785-3794.
145. Vekrellis K., Xilouri M., Emmanouilidou E., Rideout H. J., and, Stefanis L., (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 10, 1015-1025.
146. Vendruscolo M., Knowles T. P., and, Dobson C. M., (2011) Protein solubility and protein homeostasis: a generic view of protein misfolding disorders. Cold Spring Harb. Perspect. Med. 3, a010454. doi: 10.1101/cshperspect.a010454.
147. Verma M., Sharma A., Naidu S., Bhadra A. K., Kukreti R., and, Taneja V., (2012) Curcumin prevents formation of polyglutamine aggregates by inhibiting Vps36, a component of the ESCRT-II complex. PLoS ONE 7, e42923.
148. Wang H., Duennwald M. L., Roberts B. E., et al,. (2008) Direct and selective elimination of specific prions and amyloids by 4,5- dianilinophthalimide and analogs. Proc. Natl Acad. Sci. USA 105, 7159-7164.
149. Willingham S., Outeiro T. F., DeVit M. J., Lindquist S. L., and, Muchowski P. J., (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302, 1769-1772.
150. Winkler J., Tyedmers J., Bukau B., and, Mogk A., (2012) Chaperone networks in protein disaggregation and prion propagation. J. Struct. Biol. 179, 152-160.
151. Witt S. N., and, Flower T. R., (2006) alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease. FEMS Yeast Res. 6, 1107-1116.
152. Woodman B., Butler R., Landles C., Lupton M. K., Tse J., Hockly E., Moffitt H., Sathasivam K., and, Bates G. P., (2007) The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72, 83-97.
153. Xiong Y., Coombes C. E., Kilaru A., Li X., Gitler A. D., Bowers W. J., Dawson V. L., Dawson T. M., and, Moore D. J., (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6, e1000902.
154. Yankner B. A., Lu T., and, Loerch P., (2008) The aging brain. Annu. Rev. Pathol. 3, 41-66.
155. Yeger-Lotem E., Riva L., Su L. J., et al,. (2009) Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat. Genet. 41, 316-323.
156. Zabrocki P., Bastiaens I., Delay C., Bammens T., Ghillebert R., Pellens K., De Virgilio C., Van Leuven F., and, Winderickx J., (2008) Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim. Biophys. Acta 1783, 1767-1780.
157. Zarranz J. J., Alegre J., Gomez-Esteban J. C., et al,. (2004) The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.
158. Zhang X., Smith D. L., Meriin A. B., et al,. (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl Acad. Sci. USA 102, 892-897.
159. Zheng X. Y., Yang M., Tan J. Q., Pan Q., Long Z. G., Dai H. P., Xia K., Xia J. H., and, Zhang Z. H., (2008) Screening of LRRK2 interactants by yeast 2-hybrid analysis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 33, 883-891.
160. Zimprich A., Benet-Pages A., Struhal W., et al,. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168-175.
161. Zwilling D., Huang S. Y., Sathyasaikumar K. V., et al,. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874.